Inibsacain

Bupivacaine Hydrochloride with Epinephrine, the active ingredient in Inibsacain, is a local anesthetic (amide type) presented as a sterile solution for dental infiltration use. It provides prolonged numbness for dental procedures and oral surgery in adult patients. GNH USA supplies Inibsacain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inibsacain is a local anesthetic indicated for procedures involving the oral cavity and related tissues. - Dental procedures: provides reliable numbness for extractions, restorations, and periodontal therapy. - Oral surgery: enables infiltration anesthesia for minor surgical interventions such as biopsies and soft‑tissue excisions. - Endodontic treatment: facilitates pain control during root‑canal therapy and related procedures.

Adverse reactions may occur following administration of Inibsacain.

Common Side Effects: - Transient tingling or numbness at the injection site - Mild headache - Temporary increase in heart rate - Localized swelling or bruising

Serious or Rare Side Effects: - Cardiovascular toxicity such as arrhythmia or hypotension - Central nervous system effects including seizures or loss of consciousness - Severe allergic reaction (anaphylaxis) - Persistent paresthesia or nerve injury

Inibsacain should be used with attention to patient safety and proper handling. - Patient assessment: evaluate cardiac history and potential hypersensitivity before use. - Dose calculation: calculate based on body weight and maximum recommended limits. - Monitoring: observe for signs of systemic toxicity during and after administration. - Drug interactions: avoid concurrent use with other potent local anesthetics or vasoconstrictors without guidance. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Inibsacain may interact with other medications that affect cardiac or nervous system function.

Major Interactions (Avoid): - Other local anesthetics: risk of cumulative toxicity. - Beta‑blockers: may enhance bradycardia when combined with epinephrine. - Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for prolonged bleeding at injection site. - Diuretics: may alter plasma concentration of bupivacaine. - Calcium channel blockers: potential additive cardiac effects.